Close Menu

NEW YORK (GenomeWeb) – Investment bank Piper Jaffray today initiated coverage of cancer diagnostics firm OncoCyte with an Overweight rating and a $6 target on the company's stock.

In a research note, analyst William Quirk said that in his view OncoCyte's test, called DetermaVu, is potentially best in class for lung cancer diagnosis, and he believes the US Centers for Medicare & Medicaid Services could start reimbursing for the test as early as late 2020.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers trace DNA on a clay pipe found at a former slave site to a population that lives in what is now Sierra Leone, the Washington Post reports.

Two researchers report on their genetic analysis of samples from a shawl thought to belong to a victim of Jack the Ripper, ScienceInsider reports.

Japan is to release rules governing some gene-edited food, according to NHK World.

In PLOS this week: computational strategy for improving gene set analysis testing, miRNAs linked to sleep apnea, and more.